Jean van Wyk

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study

Jean van Wyk, Faïza Ajana, Fiona Bisshop et al. · Clinical Infectious Diseases · 2020 · 257 citations · Full text

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2019 · 201 citations · Full text

Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial

Shahin Lockman, Sean S. Brummel, Lauren Ziemba et al. · The Lancet · 2021 · 152 citations · Full text

Treatment And Prevention, Antiviral Drug Development, Antiviral Therapy +9

Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial

Josep M. Llibre, Carlos Brites, Chien‐Yu Cheng et al. · Clinical Infectious Diseases · 2022 · 152 citations · Full text

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial

Olayemi Osiyemi, Stéphane De Wit, Faïza Ajana et al. · Clinical Infectious Diseases · 2022 · 123 citations · Full text